OOIR: Observatory of International Research

Papers

(The TQCC of European Journal of Heart Failure is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Epidemiology of heart failure	974
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	856
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Soci	619
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio‐O	368
Epidemiology, pathophysiology and contemporary management of cardiogenic shock – a position statement from the Heart Failure Association of the European Society of Cardiology	247
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), th	222
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial	197
COVID‐19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease	190
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and	184
Self‐care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology	184
Heart failure in COVID‐19 patients: prevalence, incidence and prognostic implications	169
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial	162
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology	159
The impact of COVID‐19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic	149
Pulmonary artery pressure‐guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart F	148
The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019	134
Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: the FRAGILE‐HF cohort study	124
Angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID‐19 infection in a multi‐site UK acute hospital trust	115
Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy	111
Depression and heart failure: the lonely comorbidity	104
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study	104
Circulating cardiovascular microRNAs in critically ill COVID‐19 patients	100
Primary results of long‐term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implan	99
Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care	98
Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology	97

Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID‐19. Results of the Cardio‐COVID‐Italy multicentre study	95
An expert consensus document on the management of cardiovascular manifestations of Fabry disease	95
Management of heart failure patients with COVID‐19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association	94
Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatme	94
Ultrasound imaging of congestion in heart failure: examinations beyond the heart	92
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial	90
Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper	90
A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF	89
Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure	87
Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF	87
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA)	87
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)	86
Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction	84
Temporal trends in decompensated heart failure and outcomes during COVID‐19: a multisite report from heart failure referral centres in London	82
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure	81
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta‐analysis	80
Telemonitoring versus standard care in heart failure: a randomised multicentre trial	79
Association of COVID‐19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection	78
Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient‐level database analysis	77
Haemodynamic characteristics of COVID‐19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization	75
Trial characteristics associated with under‐enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review	73
Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction	73
Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC	73
Characterization of NT‐proBNP in a large cohort of COVID‐19 patients	72
Regional adiposity and heart failure with preserved ejection fraction	72
Cachexia, muscle wasting, and frailty in cardiovascular disease	72
Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis	70
Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients – a prospective cohort study	69
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction	69
Antigen carbohydrate 125 as a biomarker in heart failure: a narrative review	68
Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction	68
Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction	68
Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta‐regression in the past four decades	67
Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta‐analysis of screening studies	66
Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure	65
Myocarditis following COVID‐19 vaccine: incidence, presentation, diagnosis, pathophysiology, therapy, and outcomes put into perspective. A clinical consensus document supported by the Heart	64
Improving exercise capacity and quality of life using non‐invasive heart failure treatments: evidence from clinical trials	64
Heart failure management during the COVID‐19 outbreak in Italy: a telemedicine experience from a heart failure university tertiary referral centre	63
Caring for people with heart failure and many other medical problems through and beyond the COVID‐19 pandemic: the advantages of universal access to home telemonitoring	63
Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology	62
Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE‐MI): design and baseline characteristics	62
The cancer patient and cardiology	61
Ejection fraction and mortality: a nationwide register‐based cohort study of 499 153 women and men	61
Sodium–glucose co‐transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the EMPULSE trial	61
Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy	60
Effect of dapagliflozin on anaemia in DAPA‐HF	59
Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subje	59
Digital health care solution for proactive heart failure management with the Cordella Heart Failure System: results of the SIRONA first‐in‐human study	58
Contemporary survival trends and aetiological characterization in non‐ischaemic dilated cardiomyopathy	52
Congestion in heart failure: a circulating biomarker‐based perspective. A review from the Biomarkers Working Group of the Heart Failure Association, European Society of Cardiology	51

A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction – insights from the ESC‐HFA EORP Heart Failure Long‐Term Regist	51
Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy	51
Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the AC‐TIVE study, an Italian nationwide survey	50
Italian Society of Interventional Cardiology (GIse) registry Of Transcatheter treatment of mitral valve regurgitaTiOn (GIOTTO): impact of valve disease aetiology and r	50
One‐year results of the first‐in‐man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study	49
OUTSTEP‐HF: randomised controlled trial comparing short‐term effects of sacubitril/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fr	48
In‐hospital care in acute heart failure during the COVID‐19 pandemic: insights from the German‐wide Helios hospital network	48
A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF‐HFpEF	48
Coronary microvascular dysfunction is associated with exertional haemodynamic abnormalities in patients with heart failure with preserved ejection fraction	48
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial	47
Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy – A clinical consensus statement of the Heart Failure Association and Eu	47
Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo‐controlled, non‐inferiority ARIES HM3 trial	47
Decreases in acute heart failure hospitalizations during COVID‐19	47
High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality	47
Virtual optimization of guideline‐directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT‐HF pilot study	45
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC‐HF baseline characteristics and comparison with contemporary clinical trials	43
Guideline‐directed medical therapy for heart failure does not exist: a non‐judgmental framework for describing the level of adherence to evidence‐based drug treatments for patients with a reduced ejec	43
Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology	43
Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology	42
Recovery of cardiac function following COVID‐19 – ECHOVID‐19: a prospective longitudinal cohort study	42
Phenotyping heart failure patients for iron deficiency and use of intravenous iron therapy: data from the Swedish Heart Failure Registry	42
Association between renin–angiotensin–aldosterone system inhibitor use and COVID‐19 hospitalization and death: a 1.4 million patient nationwide registry analysis	42
Urinary peptides in heart failure: a link to molecular pathophysiology	41
SARS‐CoV‐2‐related myocarditis‐like syndromes Shakespeare's question: what's in a name?	41
Use of biomarkers to diagnose and manage cardiac amyloidosis	38
Long‐term clinical experience with cardiac contractility modulation therapy delivered by the Optimizer Smart system	38
Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the Eu	38
Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata	38
Splanchnic nerve modulation in heart failure: mechanistic overview, initial clinical experience, and safety considerations	38
Transcatheter tricuspid valve repair in the setting of heart failure with preserved or reduced left ventricular ejection fraction	37
Challenges and future perspectives of transcatheter tricuspid valve interventions: adopt old strategies or adapt to new opportunities?	37
Cardiac, renal, and metabolic effects of sodium–glucose co‐transporter 2 inhibitors: a position paper from the European Society of Cardiology ad‐hoc task force on sodium–glucose co‐transporter 2 inhib	37
Transapical mitral valve implantation for treatment of symptomatic mitral valve disease: a real‐world multicentre experience	36
Surgical ablation of the right greater splanchnic nerve for the treatment of heart failure with preserved ejection fraction: first‐in‐human clinical trial	36
Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care	36
The combination of carboxy‐terminal propeptide of procollagen type I blood levels and late gadolinium enhancement at cardiac magnetic resonance provides additional prognostic information in idiopathic	36
Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial	36
Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index	36
Telemonitoring in patients with chronic heart failure and moderate depressed symptoms: results of the Telemedical Interventional Monitoring in Heart Failure (TIM‐HF) study	36
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced	35
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA‐HF trial	34
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF	34
Characteristics and outcomes of patients screened for transcatheter mitral valve implantation: 1‐year results from the CHOICE‐MI registry	34
Worsening renal function in acute heart failure in the context of diuretic response	34
Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI	34
Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of th	34
The HFA‐PEFF and H₂FPEF scores largely disagree in classifying patients with suspected heart failure with preserved ejection fraction	34
A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure	33
Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of	33
Intravenous iron in patients with heart failure and iron deficiency: an updated meta‐analysis	33
Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high‐risk acute heart failure patients	32
Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction	32
Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial	32
Use of sodium–glucose co‐transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry	32
Serum potassium in the PARADIGM‐HF trial	32
Prevalence, characteristics and outcomes of older patients with hereditary versus wild‐type transthyretin amyloid cardiomyopathy	32
Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT‐CHF	32
Pathogenesis and management of myocardial injury in coronavirus disease 2019	32
Serum uric acid, influence of sacubitril–valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON‐HF	32
Association between dosing and combination use of medications and outcomes in heart failure with reduced ejection fraction: data from the Swedish Heart Failure Registry	32
Incidence and risk factors for pacemaker implantation in light‐chain and transthyretin cardiac amyloidosis	31
Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis	31
COVID‐19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology	31
Epicardial fat in heart failure with reduced versus preserved ejection fraction	31
Natural history and impact of treatment with tafamidis on major cardiovascular outcome‐free survival time in a cohort of patients with transthyretin amyloidosis	31
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction	30
Concentration‐dependent clinical and prognostic importance of high‐sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the EMPEROR<	30
Cardiac magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities	30
Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology	30
The ergoreflex: how the skeletal muscle modulates ventilation and cardiovascular function in health and disease	30
Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaire	30
Dietary interventions and nutritional supplements for heart failure: a systematic appraisal and evidence map	30
European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the	29
Efficacy and safety of sodium–glucose co‐transporter 2 inhibition according to left ventricular ejection fraction in DAPA‐HF	29
Myocardial work and vascular dysfunction are partially improved at 12 months after COVID‐19 infection	29
Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure	29
Early risk stratification in patients with cardiogenic shock irrespective of the underlying cause – the Cardiogenic Shock Score	29
Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA‐HF	29
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial	28
Natriuresis‐guided therapy in acute heart failure: rationale and design of the Pragmatic Urinary Sodium‐based treatment algoritHm in Acute Heart Failure (PUSH‐AHF) tri	28

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart fai	28
Eligibility for mechanical circulatory support devices based on current and past randomised cardiogenic shock trials	28
Prognostic value of cardiopulmonary exercise testing in cardiac amyloidosis	28
The significance of left ventricular ejection time in heart failure with reduced ejection fraction	27
Excess out‐of‐hospital deaths during the COVID‐19 outbreak: evidence of pulmonary embolism as a main determinant	27
Head‐to‐head comparison of contemporary heart failure risk scores	27
Epicardial adipose tissue related to left atrial and ventricular function in heart failure with preserved versus reduced and mildly reduced ejection fraction	27
How can sodium–glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron‐deficient? Implications for understanding iron homeostasis in heart failure	27
Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm A	27
Proteomics to improve phenotyping in obese patients with heart failure with preserved ejection fraction	27
Practical outpatient management of worsening chronic heart failure	27
Early benefit with empagliflozin in heart failure with preserved ejection fraction: insights from the EMPEROR‐Preserved trial	26
Prevention of heart failure events with sodium–glucose co‐transporter 2 inhibitors across a spectrum of cardio‐renal‐metabolic risk	26
Connecting epicardial adipose tissue and heart failure with preserved ejection fraction: mechanisms, management and modern perspectives	26
Benefit of buspirone on chemoreflex and central apnoeas in heart failure: a randomized controlled crossover trial	26
Value of the HFA‐PEFF and H₂FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis	26
National trends in heart failure mortality in men and women, United Kingdom, 2000–2017	26
Impact of ischaemic aetiology on the efficacy of intravenous ferric carboxymaltose in patients with iron deficiency and acute heart failure: insights from the AFFIRM‐AHF trial	26
Transfer of a human gene variant associated with exceptional longevity improves cardiac function in obese type 2 diabetic mice through induction of the SDF‐1/CXCR4 signalling pat	26
Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta‐analysis	26
Atrial amyloidosis: mechanisms and clinical manifestations	26
Endovascular ablation of the right greater splanchnic nerve in heart failure with preserved ejection fraction: early results of the REBALANCE‐HF trial roll‐in cohort	26
Frequency, trends and institutional variation in 30‐day all‐cause mortality and unplanned readmissions following hospitalisation for heart failure in Australia and New Zealand	25
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO‐DKD trial	25
Incorporation of natriuretic peptides with clinical risk scores to predict heart failure among individuals with dysglycaemia	25
Effects of hyperkalaemia and non‐adherence to renin–angiotensin–aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity‐matched study	25
Pharmacotherapy for heart failure with reduced ejection fraction and health‐related quality of life: a systematic review and meta‐analysis	25
Effects of combined renin–angiotensin–aldosterone system inhibitor and beta‐blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT‐CHF and	25
Long‐term survival and life expectancy following an acute heart failure hospitalization in Australia and New Zealand	25
Systemic embolism in amyloid transthyretin cardiomyopathy	25
In‐hospital initiation of quadruple medical therapy for heart failure: making the post‐discharge vulnerable phase far less vulnerable	25
Diagnostic scores predict morbidity and mortality in patients hospitalized for heart failure with preserved ejection fraction	24
Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF	24
Sex differences among patients with transthyretin amyloid cardiomyopathy – from diagnosis to prognosis	24
Cardiac remodelling – Part 2: Clinical, imaging and laboratory findings. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology	24
Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT	24
Intravenous immunoglobulin therapy in adult patients with idiopathic chronic cardiomyopathy and cardiac parvovirus B19 persistence: a prospective, double‐blind, randomized, placebo‐controll	24
Integration of imaging and circulating biomarkers in heart failure: a consensus document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiolo	24
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR‐Preserved trial	24
Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium	24
Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA‐REG OUTCOME trial	24
Left atrial disease and left atrial reverse remodelling across different stages of heart failure development and progression: a new target for prevention and treatment	24
Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline‐directed medical therapy in heart failure with reduced ejection fraction	23
Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial	23
Short‐term effects of dapagliflozin on maximal functional capacity in heart failure with reduced ejection fraction (DAPA‐VO₂): a randomized clinical trial	23
Cardiac output states in patients with severe functional tricuspid regurgitation: impact on treatment success and prognosis	23
Uncoupling between intravascular and distending pressures leads to underestimation of circulatory congestion in obesity	23
Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta‐analysis of randomized controlled trials	23
Effect of patient‐centered transitional care services on patient‐reported outcomes in heart failure: sex‐specific analysis of the PACT‐HF randomized controlled trial	23
Central haemodynamic abnormalities and outcome in patients with unexplained dyspnoea	23
Sex and central obesity in heart failure with preserved ejection fraction	23
Clonal haematopoiesis is associated with higher mortality in patients with cardiogenic shock	23
Impact of hospital transfer to hubs on outcomes of cardiogenic shock in the real world	23
Use of guideline‐recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence	23
Viral presence‐guided immunomodulation in lymphocytic myocarditis: an update	23
Prognostic impact of the updated 2018 HFA‐ESC definition of advanced heart failure: results from the HELP‐HF registry	22
Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction	22
Biomarker‐driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial	22
Heart failure with preserved ejection fraction according to the HFA‐PEFF score in COVID‐19 patients: clinical correlates and echocardiographic findings	22
Ventricular tachyarrhythmia detection by implantable loop recording in patients with heart failure and preserved ejection fraction: the VIP‐HF study	22
The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study	22
Practical algorithms for early diagnosis of heart failure and heart stress using NT‐proBNP: A clinical consensus statement from the Heart Failure Association of the ESC	22
Effects of an outpatient intervention comprising nurse‐led non‐invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (AMULET study):	22
A machine learning risk score predicts mortality across the spectrum of left ventricular ejection fraction	21
Predictors of relapse, death or heart transplantation in myocarditis before the introduction of immunosuppression: negative prognostic impact of female gender, fulminant onset, lower ejection fraction	21
A randomized clinical trial on the short‐term effects of 12‐week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results fr	21
Prognostic impacts of dynamic cardiac structural changes in heart failure patients with preserved left ventricular ejection fraction	21
Genetic and phenotypic profiling of supranormal ejection fraction reveals decreased survival and underdiagnosed heart failure	21
High selenium levels associate with reduced risk of mortality and new‐onset heart failure: data from PREVEND	21
Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost‐effectiveness analysis utilising AFFIRM‐AHF	21
Additional burden of iron deficiency in heart failure patients beyond the cardio‐renal anaemia syndrome: findings from the BIOSTAT‐CHF study	21
Clinical characteristics and 1‐year outcomes in hospitalized patients with heart failure with preserved ejection fraction: results from the China Cardiovascular Association Database‐Heart F	21
Sex‐based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan	21
Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Gro	21
Acceleration of kidney function decline after incident hospitalization with cardiovascular disease: the Stockholm CREAtinine Measurements (SCREAM) project	20
Design of a prospective patient‐level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure	20
Cardiac contractility modulation therapy improves health status in patients with heart failure with preserved ejection fraction: a pilot study (CCM‐HFpEF)	20
Guidance on the management of left ventricular assist device (LVAD) supported patients for the non‐LVAD specialist healthcare provider: executive summary	20
Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta‐analysis	20
Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans	20
Use of patient‐reported outcomes in heart failure: from clinical trials to routine practice	20
Acetazolamide in Decompensated Heart Failure with Volume Overload trial (ADVOR): baseline characteristics	20
Advanced cancer is also a heart failure syndrome: a hypothesis	20
Effect of sacubitril/valsartan vs. enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial	20
Peripheral and pulmonary effects of inorganic nitrite during exercise in heart failure with preserved ejection fraction	20
Contributions of cardiac dysfunction and volume status to central haemodynamics in chronic heart failure	19
Device‐based remote monitoring strategies for congestion‐guided management of patients with heart failure: a systematic review and meta‐analysis	19
Clinical inertia and medical therapy for heart failure: the unintended harms of ‘first, do no harm’	19
Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry	19
Plasma biomarkers associated with adverse outcomes in patients with calcific aortic stenosis	19
A global perspective on the management and outcomes of peripartum cardiomyopathy: a systematic review and meta‐analysis	19
Oral sucrosomial iron improves exercise capacity and quality of life in heart failure with reduced ejection fraction and iron deficiency: a non‐randomized, open‐label, proof‐of‐concept study	19
Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Reduced	19
The association between heart failure and incident cancer in women: an analysis of the Women's Health Initiative	19
Change in ejection fraction and long‐term mortality in adults referred for echocardiography	19